These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 22613132)

  • 1. Inhibition of forebrain μ-opioid receptor signaling by low concentrations of rimonabant does not require cannabinoid receptors and directly involves μ-opioid receptors.
    Zádor F; Otvös F; Benyhe S; Zimmer A; Páldy E
    Neurochem Int; 2012 Aug; 61(3):378-88. PubMed ID: 22613132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CB1 receptor-independent actions of SR141716 on G-protein signaling: coapplication with the mu-opioid agonist Tyr-D-Ala-Gly-(NMe)Phe-Gly-ol unmasks novel, pertussis toxin-insensitive opioid signaling in mu-opioid receptor-Chinese hamster ovary cells.
    Cinar R; Szücs M
    J Pharmacol Exp Ther; 2009 Aug; 330(2):567-74. PubMed ID: 19448142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CB(2) cannabinoid receptor antagonist SR144528 decreases mu-opioid receptor expression and activation in mouse brainstem: role of CB(2) receptor in pain.
    Páldy E; Bereczki E; Sántha M; Wenger T; Borsodi A; Zimmer A; Benyhe S
    Neurochem Int; 2008 Dec; 53(6-8):309-16. PubMed ID: 18804501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Noladin ether, a putative endocannabinoid, inhibits mu-opioid receptor activation via CB2 cannabinoid receptors.
    Páldyová E; Bereczki E; Sántha M; Wenger T; Borsodi A; Benyhe S
    Neurochem Int; 2008 Jan; 52(1-2):321-8. PubMed ID: 17698254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low dosage of rimonabant leads to anxiolytic-like behavior via inhibiting expression levels and G-protein activity of kappa opioid receptors in a cannabinoid receptor independent manner.
    Zádor F; Lénárt N; Csibrány B; Sántha M; Molnár M; Tuka B; Samavati R; Klivényi P; Vécsei L; Marton A; Vizler C; Nagy GM; Borsodi A; Benyhe S; Páldy E
    Neuropharmacology; 2015 Feb; 89():298-307. PubMed ID: 25446673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Micromolar concentrations of rimonabant directly inhibits delta opioid receptor specific ligand binding and agonist-induced G-protein activity.
    Zádor F; Kocsis D; Borsodi A; Benyhe S
    Neurochem Int; 2014 Feb; 67():14-22. PubMed ID: 24508403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Constitutive activity of the cannabinoid CB1 receptor regulates the function of co-expressed Mu opioid receptors.
    Canals M; Milligan G
    J Biol Chem; 2008 Apr; 283(17):11424-34. PubMed ID: 18319252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AM-251 and rimonabant act as direct antagonists at mu-opioid receptors: implications for opioid/cannabinoid interaction studies.
    Seely KA; Brents LK; Franks LN; Rajasekaran M; Zimmerman SM; Fantegrossi WE; Prather PL
    Neuropharmacology; 2012 Oct; 63(5):905-15. PubMed ID: 22771770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rimonabant, a potent CB1 cannabinoid receptor antagonist, is a Gα
    Porcu A; Melis M; Turecek R; Ullrich C; Mocci I; Bettler B; Gessa GL; Castelli MP
    Neuropharmacology; 2018 May; 133():107-120. PubMed ID: 29407764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Altered gene expression and functional activity of opioid receptors in the cerebellum of CB1 cannabinoid receptor knockout mice after acute treatments with cannabinoids.
    Páldyová E; Bereczki E; Sántha M; Wenger T; Borsodi A; Benyhe S
    Acta Biol Hung; 2007; 58 Suppl():113-29. PubMed ID: 18297798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mu-opioid and CB1 cannabinoid receptors of the dorsal periaqueductal gray interplay in the regulation of fear response, but not antinociception.
    Godoi MM; Junior HZ; da Cunha JM; Zanoveli JM
    Pharmacol Biochem Behav; 2020 Jul; 194():172938. PubMed ID: 32376258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Central HIV-1 Tat exposure elevates anxiety and fear conditioned responses of male mice concurrent with altered mu-opioid receptor-mediated G-protein activation and β-arrestin 2 activity in the forebrain.
    Hahn YK; Paris JJ; Lichtman AH; Hauser KF; Sim-Selley LJ; Selley DE; Knapp PE
    Neurobiol Dis; 2016 Aug; 92(Pt B):124-36. PubMed ID: 26845176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual effects of DAMGO [D-Ala2,N-Me-Phe4,Gly5-ol]-enkephalin and CTAP (D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2) on adenylyl cyclase activity: implications for mu-opioid receptor Gs coupling.
    Szücs M; Boda K; Gintzler AR
    J Pharmacol Exp Ther; 2004 Jul; 310(1):256-62. PubMed ID: 14996951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-mu opioid antiserum against the third external loop of the cloned mu-opioid receptor acts as a mu receptor neutral antagonist.
    Guarna M; Bartolini A; Ghelardini C; Galeotti N; Bracci L; Stefano GB; Bianchi E
    Brain Res Mol Brain Res; 2003 Nov; 119(1):100-10. PubMed ID: 14597234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mu opioid receptor activation enhances regulator of G protein signaling 4 association with the mu opioid receptor/G protein complex in a GTP-dependent manner.
    Santhappan R; Crowder AT; Gouty S; Cox BM; Côté TE
    J Neurochem; 2015 Oct; 135(1):76-87. PubMed ID: 26119705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of the binding of [3H][Dmt1]H-Dmt-D-Arg-Phe-Lys-NH2, a highly potent opioid peptide.
    Neilan CL; Janvey AJ; Bolan E; Berezowska I; Nguyen TM; Schiller PW; Pasternak GW
    J Pharmacol Exp Ther; 2003 Aug; 306(2):430-6. PubMed ID: 12663687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of extracellular signal-regulated kinase (ERK) by opioid and cannabinoid receptors that are expressed in the same cell.
    Korzh A; Keren O; Gafni M; Bar-Josef H; Sarne Y
    Brain Res; 2008 Jan; 1189():23-32. PubMed ID: 18068691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Powerful inhibitory action of mu opioid receptors (MOR) on cholinergic interneuron excitability in the dorsal striatum.
    Ponterio G; Tassone A; Sciamanna G; Riahi E; Vanni V; Bonsi P; Pisani A
    Neuropharmacology; 2013 Dec; 75():78-85. PubMed ID: 23891638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphorylation of the mu-opioid receptor at tyrosine 166 (Tyr3.51) in the DRY motif reduces agonist efficacy.
    Clayton CC; Bruchas MR; Lee ML; Chavkin C
    Mol Pharmacol; 2010 Mar; 77(3):339-47. PubMed ID: 19959593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A real-time, fluorescence-based assay for measuring μ-opioid receptor modulation of adenylyl cyclase activity in Chinese hamster ovary cells.
    Knapman A; Abogadie F; McIntrye P; Connor M
    J Biomol Screen; 2014 Feb; 19(2):223-31. PubMed ID: 23989451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.